Yeah, absolutely. So... We knew Q4 was going to be challenging in advance of Q4, in HHC in particular. We moved to put price increases in place not quickly enough. It took too long for those to root in, given the lower volume we experienced at the same time during that quarter. So, you know, what are we doing about it? You know, because this is obviously top of... you know, our list, Rosemarie. You know, we are aggressively revaluing, revalidating our cost reduction efforts that have been already underway there. Those have been added to by the GBU leader. The pricing actions that we already had in flight have been increased and enhanced.

Jan 16, 2025 / receipt, needs a key / Celeste Mastin, CEO | earnings call 2025-01-16 | transcript 9b58bd20-140d-432c-8707-b646f0b59f6a | chars 49540-50185 | segment 50

Senior Application Specialist, Water-Based Barrier Coatings | {"ats": "workday", "city": null, "state": null, "job_id": "/job/France/Senior-Application-Specialist--Water-Based-Barrier-Coatings_R26_000

company_statement / Sep 15, 2026 / receipt

Master Mechanic | {"ats": "workday", "city": "Frankfort", "state": "IL", "job_id": "/job/Frankfort-Illinois-USA/Master-Mechanic_R26_0000002175", "remote": false, "category": "other", "function": "othe

company_statement / Sep 15, 2026 / receipt

Senior R&D Scientist - Sustainable Barrier Coatings for Paper | {"ats": "workday", "city": null, "state": null, "job_id": "/job/Mindelo-Porto-Portugal/Senior-R-D-Scientist---Sustainable-Barrier-Coatin

company_statement / Sep 15, 2026 / receipt

Community Affairs and Philanthropy Manager | {"ats": "workday", "city": "St. Paul", "state": "MN", "job_id": "/job/St-Paul-Minnesota-USA/Community-Affairs-and-Philanthropy-Manager_R26_0000001635", "re

company_statement / Sep 15, 2026 / receipt

Based on consensus 2026 EBITDA and estimated $55M run-rate synergies

ir_statement / Sep 15, 2026 / receipt

Establishes a scaled, innovation-led global medical platform, advancing us toward our near term $100M EBITDA target

ir_statement / Sep 15, 2026 / receipt

Pre-Synergy / Post-Synergy (1) (IFRS) 12.9X / <8X

ir_statement / Sep 15, 2026 / receipt

Europe & India direct salesforce

ir_statement / Sep 15, 2026 / receipt

Significant emerging market efficiencies

ir_statement / Sep 15, 2026 / receipt

Specialized medical manufacturing footprint (UK, Germany, France, Thailand, India)

ir_statement / Sep 15, 2026 / receipt

Application of H.B. Fuller indirect sourcing capabilities across AMS

ir_statement / Sep 15, 2026 / receipt

Leverages H.B. Fuller’s U.S. commercial channel, accelerating AMS’ product U.S. penetration

ir_statement / Sep 15, 2026 / receipt